Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried.

Biotechnology

Pharmaceutical

Splisense

Splisense's headquarters in Jerusalem, Israel

Description

People (3)

Gili Hart

Lital Friedman

Tamar Mordechai

Jobs